For U.S. Healthcare Professionals Only
Prescribing Information
Important Safety Information  |   Prescribing Information For U.S. Healthcare Professionals Only

Important Safety Information: SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One. View More

A A A

Injection Technique

Injection
Demonstration Video

Learn how
to inject
Synvisc-One.

C.L.A.S.S. knee injection process

To successfully administer Synvisc-One, remember C.L.A.S.S.

Clean the knee injection location

Clean

After marking the location for the injection, apply alcohol, and swab injection site with a povidone iodine preparation (e.g. Betadine®).*

* Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because
hyaluronan can precipitate in their presence.

Apply local anesthesia prior to knee injection

Local anesthesia

Numbing the skin with an ethyl chloride spray or lidocaine injection prior to intra-articular injection may help patients feel more comfortable.

Remove any synovial fluid before knee injection

Aspirate

Insert an 18- to 20-gauge needle; this needle size optimizes fluid dynamics and may help make aspiration and the injection easier. Aspiration confirms accurate needle placement inside the joint space and allows removal of synovial fluid and effusion.

Remove any synovial fluid or effusion before injecting Synvisc-One. Strict adherence to aseptic technique must be followed.

Inject Synvisc-One into the knee

Synvisc-One injection

Inject Synvisc-One using standard techniques; patients should flex and bend the knee 3 to 4 times following injection.

Do not inject Synvisc-One extra-articularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

Set patient expectation with post-knee injection education

Set patient expectations and post-procedure education

Tell your patients to:

  • Avoid putting a lot of strain— such as jogging, lifting or prolonged standing — on the knee for 48 hours after the injection treatment or as recommended
  • Care for mild pain or swelling at the injection site by keeping an ice pack on the knee for 10 minutes or as recommended
  • Report any side effects to you or their healthcare team

Make sure to remind them that most patients reported pain relief starting at four weeks after treatment for knee osteoarthritis with Synvisc-One.

Additional resources

For your patients

The Top 5 Must-Know Facts About Managing Your OA Knee Pain (PDF)

Discover more resources for your patients

Patient
Resources

Help patients get
the most out of
their treatment.

Indication

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children (≤21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

For SYNVISC

In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

For Synvisc-One

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc-One